HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

E-selectin up-regulation allows for targeted drug delivery in prostate cancer.

Abstract
We have used the Eos Hu03 GeneChip array, which represents over 92% of the transcribed human genome, to measure gene expression in a panel of normal and diseased human tissues. This analysis revealed that E-selectin mRNA is selectively overexpressed in prostate cancer epithelium, a finding that correlated strongly with E-selectin protein expression as assessed by immunohistochemistry. Antibodies against E-selectin that blocked function failed to impede cancer cell growth, suggesting that overexpression of E-selectin was not essential for cell growth. However, a novel auristatin E-based antibody drug conjugate (ADC), E-selectin antibody valine-citrulline monomethyl-auristatin E, was a potent and selective agent against E-selectin-expressing cancer cell lines in vitro, with the degree of cytotoxicity varying with surface antigen density. Interestingly, sensitivity to the ADC differed among cell lines from different tissues expressing similar amounts of E-selectin and was found to correlate with sensitivity to free auristatin E. Furthermore, E-selectin-expressing tumors grown as xenografts in severe combined immunodeficient mice were responsive to treatment with E-selectin antibody valine-citrulline monomethyl-auristatin E in vivo, with more than 85% inhibition of tumor growth observed in treated mice. These findings demonstrate that an E-selectin-targeting ADC has potential as a prostate cancer therapy and validates a genomics-based paradigm for the identification of cancer-specific antigens suitable for targeted therapy.
AuthorsVinay Bhaskar, Debbie A Law, Eric Ibsen, Danna Breinberg, Kellie M Cass, Robert B DuBridge, Ferdinand Evangelista, Susan M Henshall, Peter Hevezi, Jennifer C Miller, Melody Pong, Rick Powers, Peter Senter, David Stockett, Robert L Sutherland, Ursula von Freeden-Jeffry, Dorian Willhite, Richard Murray, Daniel E H Afar, Vanitha Ramakrishnan
JournalCancer research (Cancer Res) Vol. 63 Issue 19 Pg. 6387-94 (Oct 01 2003) ISSN: 0008-5472 [Print] United States
PMID14559828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • E-Selectin
  • Immunotoxins
  • Oligopeptides
  • soblidotin
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacology)
  • Antibody Specificity
  • Antineoplastic Agents (administration & dosage)
  • E-Selectin (biosynthesis, genetics, immunology)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunotoxins (immunology, metabolism, pharmacology)
  • Male
  • Mice
  • Mice, SCID
  • Oligopeptides (administration & dosage)
  • Prostatic Neoplasms (drug therapy, genetics, metabolism)
  • Up-Regulation
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: